Additional file 3 of Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

Additional file 3. Table S3 Summary of scRNAseq samples and cluster marker gene statistical analyses. Data filtering: scRNAseq sample filtering cutoffs and number of cells used in analysis. Differentially expressed genes from comparison of AZD1775-specific clusters (cell states 5-11) and DMSO cell state 4 (matching G2/M cell cycle phase) from 24 h time point in RS4;11 cells, heatmap cluster assignment (refer to Fig. S2e) and summary of pathway results. Marker gene lists for 24 h time point RS4;11 cell AZD1775-specific clusters. List of cell fate III top markers. In vivo samples: MLL-7 PDX AZD1775 treatment (28 h) cluster 6 marker genes and summary of pathway analysis; MLL-7 PDX AZD1775 treatment (day 6) corresponding pathway analysis for cells matched to 28 h cluster 6; RS4;11 in vivo marker genes for 11 clusters of data merged across treatments.

附加文件3：表S3 单细胞RNA测序（scRNAseq）样本及聚类标记基因统计分析汇总。
数据过滤：本研究分析所用scRNAseq样本的过滤阈值及分析中使用的细胞数量。
差异表达基因分析：针对RS4;11细胞24小时时间点的AZD1775特异性聚类（细胞状态5-11）与二甲基亚砜（Dimethyl Sulfoxide，DMSO）处理组细胞状态4（对应G2/M细胞周期时相）的比较所得差异表达基因；热图聚类分配（参见补充图S2e）及通路分析结果汇总。
RS4;11细胞24小时时间点AZD1775特异性聚类的标记基因列表。
细胞命运III型核心标记基因列表。
体内样本：MLL-7患者来源异种移植瘤（Patient-Derived Xenograft，PDX）经AZD1775处理28小时后的聚类6标记基因及通路分析汇总；MLL-7 PDX经AZD1775处理第6天时，对应28小时聚类6的细胞的相应通路分析结果；跨所有处理组合并的11个聚类数据集的RS4;11细胞体内标记基因。